Ascendis Pharma A/s

Sanofi-A Ventis Deutschland Gmbh

Ascendis Pharma Endocrinology Division A/s

Ascendis Pharma Endocrinology Division

Ascendis Pharma Growth Disorders Division A/s

Ascendis Pharma Oncology Division A/s

Torben Lessmann

Harald Rau

Thomas Wegge

Ulrich Hersel

Juha Punnonen

Joachim Zettler

Grethe Norskov Rasmussen

Susanne Kindermann

Kennett Sprogøe

Felix Cleemann

Guillaume Maitro

Oliver Keil

Nicola Bisek

Sebastian Stark

Tobias Voigt

Grethe Nørskov Rasmussen

Samuel Weisbrod

Silvia Kaden-Vagt

Steen Jensen

Evelyn Exner

Alina Hermann

Nina Schubert

Kennett Sprogoe

David B Rosen

Thomas Kurpiers

Anna Splanemann

Kennett Sprogoee

Kennett SprogØe

Luis Zuniga

Yang Yang-malten

Lars Holten-andersen

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Polymeric hGH prodrugs

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

Carrier-linked treprostinil prodrugs

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic hydroxyl group is conjugated to one or more polymeric carriers via secondary carbamate-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

Carrier-linked carbamate prodrug linkers

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -Lrepresented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

Prodrugs comprising an insulin linker conjugate

The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.

Long acting insulin composition

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

Dipeptide-based prodrug linkers for aliphatic amine-containing drugs

Growing community of inventors

Neustadt an der Weinstrasse, Germany

Torben Lessmann